UK markets close in 2 hours 53 minutes

Roche Holding AG (RHHBY)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
42.22+0.58 (+1.39%)
At close: 04:00PM EDT
Sign in to post a message.
  • A
    Andy
    This company is much more than a cancer drug. Way over reaction IMO. Of course it was a horrible day in the market which didn’t help.
  • w
    walkerbill76
    $SLS conversation
    Berlin 68 4 months ago
    $SLS conversation
    Ez$ 3 Nps trial data Imminent, Twin Trial that launched GLSI 2,400% in A SINGLE DAY. $SLS WILL be tripling, quadding or more. re Nps IN JUNE, the Ceo said, its Herceptin ie Roche $RHHBY when answering Analyst questions about Nps Licensing. -> IN AUG, verbatim quote 'stay tuned, we should be having an announcement here very soon". ->IN NOVEMBER, Dr M Published Data showing Nps was 'more effective' than $GLSI's drug and then also ->in NOVEMBER the NCT site was updated with a 'Completion date of Dec for *identical trial results like the data that launched $GLSI 2,400% in a single day, adding a billion four in market cap. Finally ->DEC, SEC 8K Change of Control proviso - Hold on to your hats and shares.

    2 Nps trials out there, 1 imminently due for her2 3+, Tnbc complete p3 ready, 75% reduction in previous p2B wHerceptin.Vadis a NCI sponsored true cancer prevention vaccine, should be finished as well.
  • B
    Bharath
    Why is this dropping?
  • B
    Bux
    FDA APPROVED - Roche test kits
  • H
    H
    Roche Holding AG said on Monday it has received the U.S. Food and Drug Administr...
    Roche Holding AG said on Monday it has received the U.S. Food and Drug Administr...
    www.reuters.com
  • c
    choo
    Ark Invest has begun purchasing RHHBY in their ARKG fund. I believe it's due to Roche's heavy investment in individualized cancer immunotherapy. Roche plans to deliver individualized blood testing on individuals with cancer to determine their cancer's genetic profile. The cancers genetic profile will then be used to individualize cancer therapies to the patients. Also, according to Morningstar, Roche is a wide moat stock that is very undervalued (five stars). Long!!!!!
  • B
    Bill
    You should buy ACIU (AC IMMUNE) if you want Alzheimer drug exposure, with among the best risk/rewards I have ever seen. ACIU has the broadest portfolio of development stage Azlheimer's drugs with top partners such as Biogen, Eli Lilly, Roche and AbbVie. ACIU has the potential to earn $15 bil in revenues from royalties and payments The market cap of the company is only $400 mil, with $316 mil of net cash, resulting of an enterprise value of only $87 mil. If even one of ACIU's drugs go into commercial production, the stock could go up 10x or more, with limited near-term downside due to the company's strong cash position. ACIU has several drugs in its development pipeline in both stage 1 and stage 2 development, so investors have many shots at goal. There is a huge catalyst coming up on Nov 7th when the company will host a conference on the progress of their drug candidates. Investors have not started paying attention yet, but I think that will happen shortly. I have attached a recent positive recommendation on the stock from Value Investors, which is among the most reputable investors club. https://www.valueinvestorsclub.com/idea/AC_IMMUNE_SA/9888338509
  • A
    AJ
    Roche (OTCQX:RHHBY) unit, Genentech announces that tiragolumab, a novel cancer immunotherapy designed to bind to TIGIT, has been granted Breakthrough Therapy Designation (BTD) by the FDA, in combination with Tecentriq (atezolizumab) for the first-line treatment of people with metastatic non-small cell lung cancer (NSCLC).
    Breakthrough Therapy status provides for more intensive guidance from the FDA on development, the involvement of more senior agency personnel and a rolling review of the marketing application.
  • j
    james
    $SLS conversation
    Nps Licensing ducks lined Up: Data Published by Dr Peoples in Nov. Confirms Nps Traz Synergy and Why Many Big Pharma like $rhhby will buy this Asset: Two subtypes in particular, TNBC and HER2-positive breast cancer, carry a greater mutational load, higher expression of PD-L1, and more immune infiltrate compared to hormone receptor positive breast cancers [8–11]. As such, these breast cancer subtypes may be more responsive to immunotherapeutic approaches. Therefore, the results of the planned subgroup analysis of TNBC, in which patients experienced a significant improvement in DFS with the addition of NPS to trastuzumab compared with trastuzumab alone, fit with our understanding of TNBC biology and warrant further investigation.

    Trastuzumab, an IgG1 kappa monoclonal antibody against the HER2 receptor, has been found to effect both the innate and adaptive immune system. Trastuzumab facilitates antibody-dependent cell-mediated cytotoxicity (ADCC), a function of the innate immune system; however, this ability depends on a competent adaptive immune response [12, 13]. Furthermore, trastuzumab promotes Fc receptor-mediated uptake and cross-presentation of soluble HER2 antigens by dendritic cells resulting in immune priming of naïve CD8+ T cells into HER2-specific cytotoxic T lymphocytes, an effect which may be amplified by combining with a HER2-directed vaccine [3]. Finally, treatment with the HER-directed therapy, trastuzumab, has demonstrated upregulation of PD-L1 expression on breast cancer cells in transgenic mouse models, and it is hypothesized that this serves as a possible means of trastuzumab resistance [14]. These immunologic effects of trastuzumab provide the justification for combining immunomodulators such as PD-1/PD-L1 and/or CTLA-4 targeted therapy or HER2-derived peptide vaccines with the HER-directed antibody therapy in an effort to optimize anti-tumor responses.
  • g
    greg
    Plenty of Cash and two Massively Undervalued Phase 3 Assets: SLS Secondary Asset Market Value Info:
    this was from the Nps/e75 trials in combo with $RHHBY GLSI published similar results and was up to $500M in Market cap - SLS jumped to 19 in sympathy the same day glsi went to 1.4 b in value / SLS is UNDERVALUED
    Observations from early stages of E75 trial indicated that there was a potential synergistic effect between trastuzumab and E75 vaccine. In a clinical trial study, 12 HER2 (IHC 3 +) patients received trastuzumab followed by an E75 vaccine. The patients were observed for 5 years. No cancer recurrences were seen in any of patients after 5 years of follow up (Mittendorf et al. 2012). This was followed by two other studies on the concurrent administration of E75 vaccine and trastuzumab. In the first study, high-risk HER2 breast cancer patients randomized to either traustuzumab plus nelipepimut-S (E75) + GM-CSF vaccine treatment, or only trastuzumab. There were no disease recurrences after 36 months of follow up in patients treated with trastuzumab followed by vaccination with nelipepimut-S(NCT02297698) (Mittendorf et al. 2015).
  • R
    Real Immuno Investor 10
    $SLS conversation
    Reminder while short lowlife beg for our shares: 5 catalysts due Imminently. $SLS WILL be doubling, tripling, or more. -> re Nps IN JUNE, the Ceo said, its Herceptin ie Roche $RHHBY when answering Analyst questions about Nps Licensing. -> IN AUG, verbatim quote 'stay tuned, we should be having an announcement here very soon". ->IN NOVEMBER, Dr M Published Data showing Nps was 'more effective' than $GLSI's drug and then also ->in NOVEMBER the NCT site was updated with a 'Completion date of Dec for *identical trial results like the data that launched $GLSI 2,400% in a single day, adding a billion four in market cap. Finally ->mid Dec SEC 8K Change of Control proviso - Hold on to your hats and shares.

    2 Nps trials out there, 1 imminently due for her2 3+, Tnbc complete p3 ready, 75% reduction in previous p2B wHerceptin.Vadis a NCI sponsored true cancer prevention vaccine, should be finished as well.

    Official Title: Phase II Trial of Combination Immunotherapy With Nelipepimut-S + GM-CSF (NeuVax™) and Trastuzumab in High-risk HER2+ Breast Cancer Patients
    Study Start Date : October 2014
    Estimated Primary Completion Date : December 2021
    Estimated Study Completion Date : December 2021
    https://clinicaltrials.gov/ct2/show/NCT02297698?id=NCT02636582+OR+NCT03761914+OR+NCT04040231+OR+NCT01827137+OR+NCT02737787+OR+NCT01266083+OR+NCT02297698+OR+NCT01570036+OR+NCT04229979+OR+NCT00841399+OR+NCT04024800+OR+NCT03311334+OR+NCT04163094&draw=2&rank=9&load=cart
    Nps + Herceptin is now FDA Approved for a Phase 3 trial in TNBC / Roche Has no other TNBC Agent

    Vaccine Prolongs Remission in Triple-Negative Breast Cancer
    — Effect in hard-to-treat subgroup "clinically meaningful"

    SAN FRANCISCO -- Treatment with a novel peptide vaccine appeared to delay disease recurrence in triple-negative breast cancer (TNBC) patients with low HER2 expression, a subgroup analysis of a phase II trial found.

    At a median follow-up of 26.1 months, disease recurrence occurred in 7.5% of TNBC patients who received nelipepimut-S (NeuVax) compared with 26.7% in the control arm (HR 0.26, 95% CI 0.08-0.81, P=0.01), reported Guy T. Clifton, MD, of San Antonio Military Medical Center in Texas
  • R
    Real Immuno Investor 10
    $SLS conversation
    Known catalysts incoming before the FDA Green lights Gps for AML and $800M in annual rev later this year.
    1 Nps, GLSI Twin Trial results could be worth 5x the Co Market Cap, 2. A Nps license could rocket the share price $RHHBY is a Likely suitor for TNBC 3. $BMY Meso data could launch this 10x, Should the miracle patient continue survive 4. $MRK Jointly Locked data could actually be reason for a 10-20x increase in the share price.
    As of the last update, 100% of the Gps Keytruda Ovarian cancer patients were surviving on par with best treatments. Meaning, the Unlocking of this data Must, It will show Gps key patients surviving longer than the best treatments - and without Side effects. This will be a powerful moment and it is Now just days away from officially being MID YEAR.

    ALL the Patients that we expect results on (per the PR)were enrolled as of June last year. The Data is Mature.
  • T
    TOM
    To clarify further on the two analyzers from Roche, the newest one can analyze over 4000 cases in 24 hours and have the results within four hours. There are quite a large number of analyzers in the United States and in the rest of the world. Now a patient can get their results within a few hours, not days or weeks which is important to the growth  statistics to determine what’s happening in our country in any locale.
  • R
    Real Immuno Investor 10
    $SLS conversation
    Known catalysts incoming before the FDA Green lights Gps for AML and $800M in annual rev. later this year. 1 Nps, GLSI Twin Trial results could be worth 5x the Co Market Cap, 2. A Nps license could rocket the share price $RHHBY is a Likely suitor for TNBC 3. $BMY Meso data could launch this 10x, Should the miracle patient continue survive 4. $MRK Jointly Locked data could actually be reason for a 10-20x increase in the share price.
    As of the last update, 100% of the Gps Keytruda Ovarian cancer patients were surviving on par with best treatments. Meaning, the Unlocking of this data Must, It will show Gps key patients surviving longer than the best treatments - and without Side effects. This will be a powerful moment and it is Now just days away from officially being MID YEAR.

    ALL the Patients that we expect results on (per the PR)were enrolled as of June last year. The Data is Mature.
  • k
    kC
    $SLS conversation
    Plenty of Cash and two Massively Undervalued Phase 3 Assets: SLS Secondary Asset info
    this was from the Nps/e75 trials in combo with $RHHBY GLSI published similar results and was up to $500M in Market cap - SLS jumped to 19 in sympathy the same day glsi went to 1.4 b in value / SLS is UNDERVALUED
    Observations from early stages of E75 trial indicated that there was a potential synergistic effect between trastuzumab and E75 vaccine. In a clinical trial study, 12 HER2 (IHC 3 +) patients received trastuzumab followed by an E75 vaccine. The patients were observed for 5 years. No cancer recurrences were seen in any of patients after 5 years of follow up (Mittendorf et al. 2012). This was followed by two other studies on the concurrent administration of E75 vaccine and trastuzumab. In the first study, high-risk HER2 breast cancer patients randomized to either traustuzumab plus nelipepimut-S (E75) + GM-CSF vaccine treatment, or only trastuzumab. There were no disease recurrences after 36 months of follow up in patients treated with trastuzumab followed by vaccination with nelipepimut-S(NCT02297698) (Mittendorf et al. 2015).
  • A
    Andy
    This company would have to cure cancer for it to move up significantly. Good news almost every week and ARK buying thousands of shares and it goes down or barely moves up.
  • S
    Scott
    Roche approaching another new high... Slowly but surely creating wealth for shareholders. Best in class biotech and diagnostics play IMO.